HEALTHCARE services provider TalkMed Group reported a 12.2 per cent increase in net profit for its first half ended Jun 30, 2022 on the back of higher revenue.

In a bourse filing on Tuesday (Aug 2), the mainboard-listed company said that net profit for the 6-month period rose to S$12.1 million from S$10.8 million in the year ago period. Earnings per share improved from S$0.0082 to S$0.0092.

The board declared an interim cash dividend of S$0.015 per share, up from S$0.007 per share in the year-ago period. The dividend will be paid on Aug 22.

Revenue for H1 2022 rose 12.5 per cent to S$32.5 million. TalkMed noted that the lifting of Covid-19 travel restrictions in April 2022 has resulted in an increase in the number of patient visits compared to the same corresponding period last year.

Oncology services accounted for S$31.3 million in revenue, while cellular and gene therapy related product and services made up the remainder.

TalkMed said it is “cautiously hopeful for the good performances to continue during the second half of 2022”, barring any unforeseen circumstances.

GET BT IN YOUR INBOX DAILY

Start and end each day with the latest news stories and analyses delivered straight to your inbox.

Sign UpVIEW ALL

The counter closed unchanged at S$0.39 on Tuesday, before the earnings announcement.